Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Iran denies launching ballistic missiles towards Kurdistan region of Iraq- 4 astronauts are now on their path to the moon. Here’s what happens next
- Dominating the Art of Composing: Creator Bits of knowledge
- Manual for Instructive Application for Youngsters
- 4 Creative Savvy Home Gadgets of 2024: Reforming Home Robotization and Security
- First Phosphate advances battery-grade phosphate project as analysts highlight strategic Federal support
- German mid-sized firms gloomy on outlook, survey finds
- Flat Earth, spirits and conspiracy theories – experience can shape even extraordinary beliefs
- 7 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
